RT Journal Article SR Electronic T1 Immunoglobulin A Vasculitis Following COVID-19: A French Multicenter Case Series JF The Journal of Rheumatology JO J Rheumatol FD The Journal of Rheumatology SP jrheum.220503 DO 10.3899/jrheum.220503 A1 Yanis Ramdani A1 Jean Marc Galempoix A1 Jean François Augusto A1 Eva Dekmeer A1 Laurent Perard A1 Nicole Ferreira A1 Adrien Bigot A1 Julie Magnant A1 Stéphanie Jobard A1 Elisabeth Diot A1 Marie Charlotte Besse A1 Hélène Henrique A1 François Maillot A1 Alexandra Audemard-Verger YR 2022 UL http://www.jrheum.org/content/early/2022/10/10/jrheum.220503.abstract AB Objective Immunoglobulin A vasculitis (IgAV) usually occurs following viral respiratory tract infection. In the context of the global coronavirus disease 2019 (COVID-19) pandemic, we describe a case series of patients who developed IgAV following SARS-CoV-2 infection. Methods This national multicenter retrospective study included patients with IgAV following SARS-CoV-2 infection from January 1, 2020, to January 1, 2022. Patients had histologically proven IgAV and reverse transcription PCR (RT-PCR)-proven SARS-CoV-2 infection. The interval between infection and vasculitis onset had to be < 4 weeks. Results We included 5 patients, 4 of whom were women with a mean age of 45 years. Four patients had paucisymptomatic infections and 1 required a 48-hour low-flow oxygen treatment. All 5 patients had purpuric skin involvement. Arthritis was observed in 2 patients, 3 had IgA glomerulonephritis, and 2 had digestive involvement. Three renal biopsies were performed and showed mesangial IgA deposits without any extracapillary proliferation. Median C-reactive protein was 180 (range 15.1-225) mg/L, median serum creatinine level was 65 (range 41-169) μmol/L, and 2 patients had a glomerular filtration rate < 60 mL/min. Four patients received first-line treatment with glucocorticoids. All patients had a favorable progression and 2 patients experienced minor skin relapses, one after COVID-19 vaccination. Conclusion This series describes the emergence of IgAV closely following COVID-19; we were not able to eliminate an incidental link between these events. Their disease outcomes were favorable. In most of our patients, the SARS-CoV-2 infection was paucisymptomatic, and we recommend RT-PCR tests to look for COVID-19 in patients without any evident triggers for IgAV.